公开(公告)号：US10450356B2

公开(公告)日：2019-10-22

申请号：US15228234

申请日：2016-08-04

申请人： Academisch Ziekenhuis Leiden H.O.D.N. LUMC

发明人： Jan Kessler ,  Marieke Griffioen ,  Cornelis Johannes Maria Melief ,  Jan Wouter Drijfhout

IPC分类号： C07K14/00 ,  A61K39/00 ,  C07K14/47

摘要： The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.

公开(公告)号：US09441025B2

公开(公告)日：2016-09-13

申请号：US13945335

申请日：2013-07-18

申请人： Academisch Ziekenhuis Leiden h.o.d.n. LUMC

发明人： Jan Kessler ,  Marieke Griffioen ,  Cornelis Johannes Maria Melief ,  Jan Wouter Drijfhout

IPC分类号： A61K38/00 ,  C07K14/47 ,  A61K39/00

CPC分类号： C07K14/4748 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/57 ,  A61K2039/572

摘要： The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.

摘要翻译： 本发明涉及长度不超过100个氨基酸并且包含来自人PRAME蛋白质的氨基酸序列的至少19个连续氨基酸的肽，其中所述肽包含至少一个HLA II类表位和至少一个 来自人PRAME蛋白质的氨基酸序列的HLA I类表位，以及其本身的用途或组合物中用作治疗和/或预防癌症的药物。

公开(公告)号：US20140348862A1

公开(公告)日：2014-11-27

申请号：US13945335

申请日：2013-07-18

申请人： Academisch Ziekenhuis Leiden h.o.d.n. LUMC

发明人： Jan Kessler ,  Marieke Griffioen ,  Cornelis Johannes Maria Melief ,  Jan Wouter Drijfhout

IPC分类号： C07K14/47

CPC分类号： C07K14/4748 ,  A61K39/00 ,  A61K39/0011 ,  A61K2039/57 ,  A61K2039/572

摘要： The invention relates to a peptide having a length of no more than 100 amino acids and comprising at least 19 contiguous amino acids from the amino acid sequence of the human PRAME protein, wherein the peptide comprises at least one HLA class II epitope and at least one HLA class I epitope from the amino acid sequence of the human PRAME protein and to its use as such or in a composition as a medicament for the treatment and/or prevention of cancer.

摘要翻译： 本发明涉及长度不超过100个氨基酸并且包含来自人PRAME蛋白质的氨基酸序列的至少19个连续氨基酸的肽，其中所述肽包含至少一个HLA II类表位和至少一个 来自人PRAME蛋白质的氨基酸序列的HLA I类表位，以及其本身的用途或组合物中用作治疗和/或预防癌症的药物。